Plus Net Debt from 2010 to 2026

PSTV Stock

USD 0.27 0.02 6.32%

Plus Therapeutics Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt is likely to outpace its year average in 2026. Net Debt is the total debt of Plus Therapeutics minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2001-03-31

Previous Quarter

-2.2 M

Current Value

-13.3 M

Quarterly Volatility

9.3 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.3 M, Selling General Administrative of 10.1 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or Days Sales Outstanding of 42.94. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.

Build AI portfolio with Plus Stock

Check out the analysis of Plus Therapeutics Correlation against competitors.

For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

The evolution of Net Debt for Plus Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Plus Therapeutics compares to historical norms and industry peers.

Latest Plus Therapeutics' Net Debt Growth Pattern

Below is the plot of the Net Debt of Plus Therapeutics over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Plus Therapeutics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Net Debt

Timeline

Plus Net Debt Regression Statistics

	Arithmetic Mean	731,325
	Geometric Mean	4,577,072
	Coefficient Of Variation	1,042
	Mean Deviation	6,175,562
	Median	3,291,000
	Standard Deviation	7,617,957
	Sample Variance	58T
	Range	23.3M
	R-Value	(0.18)
	Mean Square Error	60T
	R-Squared	0.03
	Significance	0.50
	Slope	(266,447)
	Total Sum of Squares	928.5T

Plus Net Debt History

	2026	4 M
	2025	3.8 M
	2024	3.3 M
	2023	-4.4 M
	2022	-12.4 M
	2021	-11.4 M
	2020	-1.4 M

Other Fundumenentals of Plus Therapeutics

Net Debt To E B I T D A

Plus Therapeutics Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Total Current Assets	Retained Earnings	Net Receivables	Short Term Investments	Short Term Debt	Common Stock	Current Deferred Revenue	Accounts Payable	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Property Plant Equipment	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.62	0.08	0.81	0.91	0.19	0.65	-0.47	0.38	0.45	0.35	0.38	0.64	0.63	-0.24	0.54	0.59	-0.61	-0.23	0.75	0.16	0.33
Total Stockholder Equity	0.62		-0.29	0.07	0.56	0.15	0.1	-0.21	0.15	0.24	0.21	0.09	0.42	0.34	0.19	0.16	0.21	-0.27	0.05	0.72	0.49	0.43
Net Debt	0.08	-0.29		0.31	-0.24	0.12	0.29	0.01	0.52	-0.45	-0.44	0.02	0.34	0.72	-0.37	0.15	0.24	-0.22	0.04	0.14	-0.68	-0.21
Total Liab	0.81	0.07	0.31		0.75	0.12	0.75	-0.48	0.37	0.41	0.29	0.45	0.49	0.54	-0.41	0.53	0.56	-0.55	-0.29	0.39	-0.2	0.15
Total Current Assets	0.91	0.56	-0.24	0.75		0.17	0.65	-0.45	0.24	0.61	0.51	0.37	0.47	0.31	-0.13	0.54	0.54	-0.55	-0.35	0.58	0.32	0.33
Retained Earnings	0.19	0.15	0.12	0.12	0.17		0.41	0.75	-0.06	0.29	0.48	-0.79	0.73	0.31	-0.23	0.81	0.82	-0.82	-0.51	0.62	-0.13	0.16
Net Receivables	0.65	0.1	0.29	0.75	0.65	0.41		-0.13	0.33	0.27	0.23	0.1	0.55	0.5	-0.24	0.75	0.74	-0.73	-0.59	0.42	-0.14	0.09
Short Term Investments	-0.47	-0.21	0.01	-0.48	-0.45	0.75	-0.13		-0.35	-0.08	0.17	-0.99	0.24	-0.12	-0.02	0.33	0.32	-0.3	-0.28	0.11	-0.13	0.01
Short Term Debt	0.38	0.15	0.52	0.37	0.24	-0.06	0.33	-0.35		-0.2	-0.28	0.31	0.18	0.53	-0.48	-0.04	0.04	-0.15	0.3	0.29	-0.16	-0.11
Common Stock	0.45	0.24	-0.45	0.41	0.61	0.29	0.27	-0.08	-0.2		0.97	0.06	0.26	-0.22	-0.05	0.38	0.37	-0.37	-0.3	0.22	-0.04	0.06
Current Deferred Revenue	0.35	0.21	-0.44	0.29	0.51	0.48	0.23	0.17	-0.28	0.97		-0.19	0.33	-0.23	-0.06	0.46	0.46	-0.46	-0.36	0.27	-0.05	0.07
Accounts Payable	0.38	0.09	0.02	0.45	0.37	-0.79	0.1	-0.99	0.31	0.06	-0.19		-0.32	0.06	0.06	-0.38	-0.38	0.38	0.3	-0.23	0.04	-0.06
Good Will	0.64	0.42	0.34	0.49	0.47	0.73	0.55	0.24	0.18	0.26	0.33	-0.32		0.74	-0.35	0.79	0.86	-0.84	-0.39	0.83	-0.16	0.23
Intangible Assets	0.63	0.34	0.72	0.54	0.31	0.31	0.5	-0.12	0.53	-0.22	-0.23	0.06	0.74		-0.31	0.47	0.57	-0.57	-0.13	0.71	-0.23	0.21
Net Tangible Assets	-0.24	0.19	-0.37	-0.41	-0.13	-0.23	-0.24	-0.02	-0.48	-0.05	-0.06	0.06	-0.35	-0.31		-0.21	-0.24	0.34	0.05	-0.28	0.16	0.06
Long Term Debt	0.54	0.16	0.15	0.53	0.54	0.81	0.75	0.33	-0.04	0.38	0.46	-0.38	0.79	0.47	-0.21		0.99	-0.92	-0.78	0.64	-0.06	0.16
Long Term Debt Total	0.59	0.21	0.24	0.56	0.54	0.82	0.74	0.32	0.04	0.37	0.46	-0.38	0.86	0.57	-0.24	0.99		-0.95	-0.72	0.71	-0.14	0.2
Capital Surpluse	-0.61	-0.27	-0.22	-0.55	-0.55	-0.82	-0.73	-0.3	-0.15	-0.37	-0.46	0.38	-0.84	-0.57	0.34	-0.92	-0.95		0.6	-0.76	0.06	-0.24
Property Plant Equipment	-0.23	0.05	0.04	-0.29	-0.35	-0.51	-0.59	-0.28	0.3	-0.3	-0.36	0.3	-0.39	-0.13	0.05	-0.78	-0.72	0.6		-0.23	0.01	-0.14
Net Invested Capital	0.75	0.72	0.14	0.39	0.58	0.62	0.42	0.11	0.29	0.22	0.27	-0.23	0.83	0.71	-0.28	0.64	0.71	-0.76	-0.23		0.25	0.39
Net Working Capital	0.16	0.49	-0.68	-0.2	0.32	-0.13	-0.14	-0.13	-0.16	-0.04	-0.05	0.04	-0.16	-0.23	0.16	-0.06	-0.14	0.06	0.01	0.25		0.38
Capital Stock	0.33	0.43	-0.21	0.15	0.33	0.16	0.09	0.01	-0.11	0.06	0.07	-0.06	0.23	0.21	0.06	0.16	0.2	-0.24	-0.14	0.39	0.38

Click cells to compare fundamentals

About Plus Therapeutics Financial Statements

Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	3.8 M	4 M
Net Debt To EBITDA	(0.35)	(0.33)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Plus Net Debt from 2010 to 2026

Latest Plus Therapeutics' Net Debt Growth Pattern

Plus Net Debt Regression Statistics

Plus Net Debt History

Other Fundumenentals of Plus Therapeutics

Plus Therapeutics Net Debt component correlations

About Plus Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Plus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY